Fewer, larger radiotherapy doses prove safe for prostate cancer patients
December 13, 2011 in Cancer(Medical Xpress) -- Less overall radiotherapy, delivered in fewer but higher doses, is as safe as standard, lower doses for treating prostate cancer, according to new research published in the Lancet Oncology today (Tuesday).
Data from the Cancer Research UK funded CHHiP trial - supported by the National Institute for Health Research and led by The Institute of Cancer Research (ICR) and The Royal Marsden NHS Foundation Trust - have been analysed by the ICRs Clinical Trials and Statistics Unit.
A total of 457 men with prostate cancer were recruited to examine the safety and side-effects of higher individual doses of radiotherapy on the bowel, bladder and sexual function. All high dose results were found to be similar to standard radiotherapy.
The men either received standard radiotherapy of 74 Gy over 37 days (2 Gy a day), 60 Gy delivered over 20 days (3 Gy a day) or 57 Gy delivered in 19 days (3 Gy per day). The next stage of the trial - which has recruited 3216 men in total - will compare outcomes in the different patient groups.
Professor David Dearnaley, lead investigator from the ICR and The Royal Marsden, said: Earlier research suggests that prostate cancer cells may be more sensitive to higher individual doses of radiotherapy than other types of cancers. This could mean giving patients larger doses of radiotherapy per hospital visit, with fewer hospital trips and less radiotherapy needed overall. Our aim is to discover if this is the case and learn more about effective radiotherapy options for men with prostate cancer. This safety data is very pleasing and we are looking forward to the results of the next phase of the trial to see if this method ultimately offers patients better tumour control or fewer side-effects.
Dr. Emma Hall from the ICRs Clinical Trials and Statistics Unit said: The finding that this treatment schedule is as safe as standard treatment has allowed us to expand the trial to include men from all over the UK. This is now the largest ever academic trial in prostate cancer with 3,216 men involved.
Around 37,000 men are diagnosed with prostate cancer every year in the UK. More than 10,000 men die from the disease annually. In the UK, radiotherapy is the most commonly used treatment to cure localised prostate cancer.
Kate Law, Cancer Research UKs clinical trials director, said: Radiotherapy remains a mainstay of treatment for prostate and many other types of cancer. These results highlight important ongoing research which is looking to further refine radiotherapy, and to help ensure that men with prostate cancer are getting the best treatment possible.
All men and their families would appreciate fewer trips to the hospital to receive treatment so we look forward to seeing the full results of this research. 2011 is the Year of Radiotherapy and its 100 years since Marie Curie won her second Nobel Prize for her work in this area. Radiotherapy is, quite wrongly, often regarded as old-fashioned by the public. But there may be greater benefits for patients in the future as we continue to learn more about its effectiveness.
More information: Dearnaley, D., et al.(2011). Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial The Lancet Oncology DOI: 10.1016/S1470-2045(11)70293-5
Provided by Cancer Research UK
-
New treatment to reduce the relapse rate in bladder cancer patients
Jan 31, 2011 |
not rated yet |
0
-
More aggressive treatment not necessary for men with a family history of prostate cancer
Oct 05, 2011 |
not rated yet |
0
-
Researchers find that aspirin reduces the risk of cancer recurrence in prostate cancer patients
May 02, 2011 |
not rated yet |
0
-
Queen's pioneers prostate cancer breakthrough
Sep 19, 2011 |
not rated yet |
0
-
Shorter radiation course for prostate cancer is effective in long-term follow-up
Sep 26, 2011 |
not rated yet |
0
-
Of mice and mental models: Neuroscientific implications of risk-optimized behavior in the mouse
May 25, 2012 |
not rated yet |
0
-
Limits to growth: Scientists identify key metastasis-enabling enzyme
May 22, 2012 |
5 / 5 (4) |
0
-
Seeing is as seeing does: Spatially-structured retinal input in early development of cortical maps
Apr 26, 2012 |
5 / 5 (4) |
1
-
Dreamless nights: Brain activity during nonrapid eye movement sleep
Apr 09, 2012 |
4.4 / 5 (12) |
0
-
Take your time: Neurobiology sheds light on the superiority of spaced vs. massed learning
Mar 28, 2012 |
4.5 / 5 (21) |
3
-
Potential Breakthrough in Seizure Control
13 hours ago
-
Popping/Cracked sternum.
18 hours ago
-
Which Mental Illness Encompasses This Problem?
18 hours ago
-
A question about drug tolerance
May 23, 2012
-
Poor nutrition leading to overeating?
May 23, 2012
-
Math and dyslexia?
May 21, 2012
- More from Physics Forums - Medical Sciences
More news stories
Skp2 activates cancer-promoting, glucose-processing Akt
HER2 and its epidermal growth factor receptor cousins mobilize a specialized protein to activate a major player in cancer development and sugar metabolism, scientists report in the May 25 issue of Cell.
Cancer
May 25, 2012 |
not rated yet |
0
|
Pancreatectomy OK without downstaging from therapy
(HealthDay) -- Pancreatectomy improves median survival in pancreatic cancer patients even when presurgical neoadjuvant therapy does not lead to radiographic downstaging of tumors, according to a study published ...
Cancer
May 25, 2012 |
not rated yet |
0
Common therapies for basal cell carcinoma offer similar survival
(HealthDay) -- For patients with superficial basal cell carcinoma (sBCC), treatment with imiquimod or photodynamic therapy (PDT) results in similar long-term tumor-free survival, according to a review published ...
Cancer
May 25, 2012 |
not rated yet |
0
Cancer may require simpler genetic mutations than previously thought
Chromosomal deletions in DNA often involve just one of two gene copies inherited from either parent. But scientists haven't known how a deletion in one gene from one parent, called a "hemizygous" deletion, can contribute ...
Cancer
May 25, 2012 |
not rated yet |
0
|
New prostate cancer screening guidelines face a tough sell, study suggests
(Medical Xpress) -- Recent recommendations from the U.S. Preventive Services Task Force (USPSTF) advising elimination of routine prostate-specific antigen (PSA) screening for prostate cancer in healthy men are likely to encounter ...
Cancer
May 25, 2012 |
not rated yet |
1
Travel to high altitudes tied to Crohn's, colitis flare-ups
(HealthDay) -- People with inflammatory bowel disease, which includes Crohn's disease and colitis, may be at increased risk for flare-ups when they fly or travel to high altitudes for skiing or mountain climbing, ...
Family history of Alzheimer's affects functional connectivity
(HealthDay) -- Cognitively normal individuals with a family history of late-onset Alzheimer's disease (AD) may display lower resting state functional connectivity in the default mode network (DMN) of the brain, ...
Transvaginal mesh op restores pelvic organ prolapse at price
(HealthDay) -- Transvaginal mesh (TVM) procedures are effective for anatomical restoration of pelvic organ prolapse (POP), but patients report a worsening of sexual function following surgery, according to ...
Tongue analysis software uses ancient Chinese medicine to warn of disease
For 5,000 years, the Chinese have used a system of medicine based on the flow and balance of positive and negative energies in the body. In this system, the appearance of the tongue is one of the measures used to classify ...
Of mice and mental models: Neuroscientific implications of risk-optimized behavior in the mouse
(Medical Xpress) -- Regardless of an organism’s biological complexity, every encephalized animal continuously makes under-informed behavioral choices that can have serious consequences. Despite its ubiquity, ...
Weight struggles? Blame new neurons in your hypothalamus
New nerve cells formed in a select part of the brain could hold considerable sway over how much you eat and consequently weigh, new animal research by Johns Hopkins scientists suggests in a study published in the May issue ...